Rate My Professor Chun Yiu Law

Dr. Chun Yiu Law serves as Clinical Associate Professor in the Sydney Medical School at the University of Sydney. His work email is chunyiu.law@sydney.edu.au. He earned a PhD in Medicine from the University of Hong Kong, where he was a finalist in the 3 Minute Thesis competition in 2015. Prior to his current role, Dr. Law was affiliated with the Division of Chemical Pathology in the Department of Pathology at Queen Mary Hospital, Hong Kong, and the Department of Pathology at the University of Hong Kong. He has contributed to the NSW Newborn Screening Programme and the Discipline of Genomic Medicine within Sydney Medical School. Dr. Law's career spans clinical biochemistry and pathology, with active involvement in diagnostic advancements.

Dr. Law's research specializations include chemical pathology, thyroid function and autoimmunity, newborn screening for spinal muscular atrophy, metabolomic profiling in cancers such as prostate and lung adenocarcinoma, inborn errors of metabolism, and genetic diagnostics. He has presented at the Hong Kong Pathology Forum, speaking on biochemical and genetic diagnosis of Alzheimer's disease in 2023 and therapeutic drug monitoring and pharmacogenomics of cytotoxic drugs in 2022. Key publications include: "Newborn screening (NBS) for spinal muscular atrophy: the 5-year experience of the NSW NBS Programme" (2023); "A prospective follow-up on thyroid function, thyroid autoimmunity, and thyroid cancer risk after COVID-19 infection" (2023); "Insights from a Prospective Follow-up of Thyroid Function and Thyroid Autoimmunity After COVID-19 Infection" (2021); "The Independent Association of TSH and Free Triiodothyronine With Subclinical Carotid Atherosclerosis in Euthyroid Individuals" (2022); "Role of non-thyroidal illness syndrome in predicting adverse outcomes in COVID-19 patients" (2021); "Mitochondrial genome content is decreased in prostate cancer overall but increased in high-grade cancer" (2017); "Limb girdle myasthenia with digenic RAPSN and a novel disease gene AK9" (2017); "Untargeted Mass Spectrometry-Based Metabolomic Profiling of Lung Adenocarcinoma" (2014); "Changing pleural fluid triglyceride levels in cirrhotic chylothorax" (2022); "Urine 'total triglyceride' for diagnosis of a rare cause of hypoglycemia" (2016); and "Fatal viral infection-associated encephalopathy in two Chinese boys: studies by whole exome sequencing" (2011). His contributions have impacted clinical diagnostics in pathology and genomics.